Citigroup Downgrades Edwards Lifesciences to Neutral
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has downgraded Edwards Lifesciences (NYSE:EW) from Buy to Neutral, indicating a change in the bank's outlook on the company's stock.
December 11, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edwards Lifesciences was downgraded by Citigroup from Buy to Neutral, which may influence investors' perception and could potentially lead to a decrease in stock price in the short term.
Analyst ratings often affect stock prices as they reflect a change in the market's view on the company's future performance. A downgrade from Buy to Neutral suggests less optimism about the company's growth prospects, which could lead to some investors selling their shares. This typically results in a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100